<DOC>
	<DOCNO>NCT00103402</DOCNO>
	<brief_summary>The purpose randomize clinical trial evaluate efficacy safety alpha adrenergic blocker Alfuzosin ( Uroxatral ) men relatively new onset chronic prostatitis/chronic pelvic pain syndrome ( CP/CPPS ) . Alfuzosin daily ( 10 mg capsule ) , FDA approve medication indication benign prostatic hyperplasia ( BPH ) . The effectiveness alfuzosin improve low urinary tract symptom patient BPH document number placebo-controlled study . A number small study also suggest alfuzosin ameliorates CP/CPPS symptom similar alpha-blockade mechanism . This study enable test hypothesis</brief_summary>
	<brief_title>Trial Compare Alfuzosin Versus Placebo Treatment Chronic Prostatitis/Chronic Pelvic Pain Syndrome</brief_title>
	<detailed_description>The two primary objective study : - To compare 12 week treatment alfuzosin versus placebo newly-diagnosed , alpha-blocker naïve CP/CPPS participant respect primary endpoint NIH-CPSI . - To evaluate safety tolerability 12 week alfuzosin newly-diagnosed , alpha-blocker naïve CP/CPPS participant . The proportion `` responder '' treatment arm compare evaluate overall safety efficacy alfuzosin compare placebo . Approximately 270 eligible patient , 135 per treatment arm , randomize followed period twelve ( 12 ) week randomization . There four clinic visit .</detailed_description>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Participant sign dated appropriate Informed Consent document . Participant male . Participant least 18 year age . Participant symptoms discomfort pain pelvic region least sixweek interval time presentation . Symptoms bothersome enough prompt physician visit present two year less . Participant evidence facultative Gram negative enterococcus value great equal 1000 CFU/ml midstream urine ( VB2 ) . Participant previously receive alfuzosin ( Uroxatral® ) , tamsulosin hydrochloride ( Flomax® ) , doxazosin mesylate ( Cardura® ) , terazosin HCL ( Hytrin® ) , alphaadrenergic receptor blocker symptoms CP/CPPS within past two year reason . Participant history prostate , penile , testicular , bladder , urethral cancer undergone pelvic radiation , systemic chemotherapy , intravesical chemotherapy . Participant history moderate severe hepatic impairment , severe renal sufficiency , severe unstable cardiovascular ( i.e . prolonged QT ) , respiratory , hematological , endocrinological , neurological somatic disorder . Participant unilateral orchialgia without pelvic symptom , active urethral stricture , neurological disease disorder affect bladder . Participant uninvestigated , significant hematuria . Participant undergone TURP , TUIP , TUIBN , TUMT , TUNA , balloon dilation prostate , open prostatectomy prostate surgery treatment cryotherapy thermal therapy . Participant neurological impairment psychiatric disorder prevent understanding consent ability comply protocol . Participant currently take exclusionary medication potent CYP3A4 inhibitor ( i.e . ketoconazole , itraconazole , ritonavir ) erythromycin .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Prostatitis</keyword>
	<keyword>Non-bacterial Prostatitis</keyword>
	<keyword>Prostatodynia</keyword>
	<keyword>Alfuzosin</keyword>
	<keyword>Alpha-adrenergic blocker</keyword>
</DOC>